Date: 27 oktober 2009
URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
Topic=3DXMRV
Ref: The list below illustrates that so far, just 16 papers have been
published on the XMRV.
XMRV papers published up to october 27, 2009
--------------------------------------------
___ Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner
J, Miller K, Kurth R, Bannert N.
Lack of evidence for xenotropic murine leukemia virus-related
virus (XMRV) in German prostate cancer patients.
Retrovirology. 2009 Oct 16;6(1):92.
___ Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS,
Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B,
Dean M, Silverman RH, Mikovits JA.
Detection of an Infectious Retrovirus, XMRV, in Blood Cells of
Patients with Chronic Fatigue Syndrome.
Science. 2009 Oct 8.
___ Yan Y, Liu Q, Kozak CA.
Six host range variants of the xenotropic/polytropic
gammaretroviruses define determinants for entry in the XPR1 cell
surface receptor.
Retrovirology. 2009 Oct 7;6(1):87.
___ Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR.
XMRV is present in malignant prostatic epithelium and is
associated with prostate cancer, especially high-grade tumors.
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16351-6.
___ Stang A, Petrasch-Parwez E, Brandt S, Dermietzel R, Meyer HE,
Stuhler K, Liffers ST, Uberla K, Grunwald T.
Unintended spread of a biosafety level 2 recombinant retrovirus.
Retrovirology. 2009 Sep 22;6:86.
___ Hong S, Klein EA, Das Gupta J, Hanke K, Weight CJ, Nguyen C,
Gaughan C, Kim KA, Bannert N, Kirchhoff F, Munch J, Silverman RH.
Fibrils of prostatic acid phosphatase fragments boost infections
with XMRV (xenotropic murine leukemia virus-related virus), a
human retrovirus associated with prostate cancer.
J Virol. 2009 Jul;83(14):6995-7003.
___ Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, Tewari M,
Multiple integrated copies and high-level production of the human
retrovirus XMRV (xenotropic murine leukemia virus-related virus)
from 22Rv1 prostate carcinoma cells.
J Virol. 2009 Jul;83(14):7353-6.
___ Bisbal C, Salehzada T.
RNase L, a crucial mediator of innate immunity and other cell
functions [French].
Med Sci (Paris). 2008 Oct;24(10):859-64.
___ Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher
M, Schlomm T.
Prevalence of human gammaretrovirus XMRV in sporadic prostate
cancer.
J Clin Virol. 2008 Nov;43(3):277-83.
___ Dong B, Silverman RH, Kandel ES.
A natural human retrovirus efficiently complements vectors based
on murine leukemia virus.
PLoS One. 2008 Sep 4;3(9):e3144.
___ Kim S, Kim N, Dong B, Boren D, Lee SA, Das Gupta J, Gaughan C,
Klein EA, Lee C, Silverman RH, Chow SA.
Integration site preference of xenotropic murine leukemia virus-
related virus, a new human retrovirus associated with prostate
cancer.
J Virol. 2008 Oct;82(20):9964-77.
___ Summers K, Crespi B.
Molecular evolution of the prostate cancer susceptibility locus
RNASEL: evidence for positive selection.
Infect Genet Evol. 2008 May;8(3):297-301.
___ McCormick AL, Brown RH Jr, Cudkowicz ME, Al-Chalabi A, Garson JA.
Quantification of reverse transcriptase in ALS and elimination
of a novel retroviral candidate.
Neurology. 2008 Jan 22;70(4):278-83.
___ Silverman RH.
A scientific journey through the 2-5A/RNase L system.
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):381-8.
___ Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D,
Derisi JL, Chow SA, Silverman RH.
An infectious retrovirus susceptible to an IFN antiviral pathway
from human prostate tumors.
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1655-60.
___ Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA,
Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH,
DeRisi JL.
Identification of a novel Gammaretrovirus in prostate tumors of
patients homozygous for R462Q RNASEL variant.
PLoS Pathog. 2006 Mar;2(3):e25. Epub 2006 Mar 31.
--------
(c) 2009 NCBI PubMed
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
